KCM
OBIO icon

Knoll Capital Management’s Orchestra BioMed OBIO Stock Holding History

Knoll Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-455,128
Closed -$421K – 37
2025
Q3 		$421K Hold
455,128
– – 0.23% 35
2025
Q2 		$170K Buy
+455,128
New +$1.33M 0.12% 36

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Knoll Capital Management's OBIO Position: Q4 2025 in Review

Knoll Capital Management sold out of Orchestra BioMed (OBIO) in Q4 2025, closing a stake of 455,128 shares — an estimated $421K sold.

Knoll Capital Management first reported a position in OBIO in Q2 2025 and held it in 2 quarters. The position peaked at $421K in Q3 2025. 63 funds tracked by Wall St. Rank hold OBIO as of Q4 2025.

  • Knoll Capital Management reported no remaining Orchestra BioMed position as of Q4 2025 after selling out during the quarter.
  • Knoll Capital Management sold 455,128 Orchestra BioMed shares in Q4 2025, an estimated $421K.
  • Knoll Capital Management first reported a position in Orchestra BioMed in Q2 2025 and held it in 2 quarters.
  • Knoll Capital Management's Orchestra BioMed position peaked at $421K in Q3 2025.
  • 63 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2025.

Based on Knoll Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.